CSClaude Soubrane

Claude Soubrane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claude Soubrane has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CT perfusion as index of activity of antiangiogenic treatment of metastatic carcinoma

    by S. Vignot, J. Spano, J. Bloch, R. Mouawad, J. M. Foult, V. Adam, C. Soubrane, D. Buthiau, D. Khayat

    3548 Background: the aim of this study was to evaluate the different Computed Tomography (CT) parameters, characterizing tissue perfusion by contrast medium in metastatis to define their relation with activity of an antiangiogenic compound, targeting the VEGF receptors 1 and 2, using this qualitative and quantitative method. Methods: 113 patients with metastatic renal cell, pancreatic, colonic carcinoma and melanoma treated with antiangiogenic compound, were studied by dynamic CT (64 slices, GE) : calculation of time to peak (TTP), positive enhancement integral (PEI), maximum slope of increase (MSI), maximum slope of decrease (MSD), blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability surface (PS) were performed. Value distributions in the normal and neoplastic wall, their variation after antiangiogenic therapies and their relation to mono and bidimensionnal or volume measurement and pathological vessel density (MVD) were evaluated. Results: BF, TTP, and especially PEI and PS were highter in tumor than in normal liver, respectively in 68, 76, 100 and 100%; PS was > 20 ml/min/100g in 100% of patients. PEI and PS decrease in 78% and 82% of patients submitted to antiangiogenic treatment at the first course. Decreased tumor perfusion (TP) was observed in patients responding to therapy, including liver metastasis. Furthermore, in 40 out of 60 patients with stable or progressive disease by RECIST, decreased TP was strongly correlated with clinical improvement. Significant correlation between PEI in tumor/PEI in the aorta and PS was found (R=0,679). Conclusion: CT perfusion could be reliable in the study of the neo-angiogenic process, characterized by an increase in vessel number, vascular permeability and flow into extra vascular spaces, better than direct measurement of the tumor or MVD count. Imaging will gain a role in monitoring targeted therapies, in the assessement of the evaluation of the antiangiogenic therapy and in the selection of patients eligible to be treated by this method. PEI in the tumor/PEI in the aorta and PS seem to be the most discriminative and predictive parameters. Others parameters (TTP, MSI, MSD) are operator and patient dependant. MTT is under evaluation as a good criterium of intersticial pressure around tumors No significant financial relationships to disclose.

  • Relationship of soluble VEGF-C and VEGF-D with clinicopathological parameters in metastatic malignant melanoma patients treated by biochemotherapy

    by R. Mouawad, J.-B. Meric, J.-P. Spano, G. Auclerc, O. Rixe, D. Khayat, C. Soubrane

    7540 Background and Objectives: Angiogenesis is essential for tumor growth & metastasis. It is controlled by angiogenic factors, one of the most important being vascular endothelial growth factor (VEGF). Although its role has been demonstrated in many malignant tumors including melanoma, the importance of other members of VEGF family (C & D) has not yet been reported. This study was designed to determine whether soluble VEGF-C & or VEGF-D correlate with clinicopathological features of metastatic malignant melanoma (MMM) patients treated by biochemotherapy. Patients & treatment: 58 patients with MMM were treated by CDDP, recombinant IL-2 & α-Interferon in 2 induction cycles. The assessment of clinical response was performed according to WHO criteria. Methods: soluble VEGF-C & D were measured before & after treatment in the serum of MMM patients and 20 healthy donors using sensitive ELISA assays. Results: circulating VEGF-C & VEGF-D were detectable, variable in all samples from either melanoma patients or healthy donors. Before therapy, only median sVEGF-C level was significantly higher (p=0.005) in MMM patients as compared to healthy donors (355 vs 156 pg/ml). No significant correlations have been established between sVEGF-C or sVEGF-D levels with age, gender or LDH. By contrast, when patients were classified according to tumor burden, only median level of sVEGF-C was significantly higher (p=0.04) in patients with high tumor burden (n=31) as compared to those with low tumor burden (n=20). When clinical response has been taken into consideration, the level of VEGF-C was higher (455 pg/ml) in biochemorefractory (n=33) as compared to responder (n=21) patients (386 pg/ml). After treatment, an increase of circulating VEGF-C & VEGF-D was observed without any relationship with clinical response. However, it is important to note that sVEGF-C increased specifically in NR patients with high tumor burden. Conclusion: our results supports the concept that pretreatment sVEGF-C or its increase after therapy in association with tumor burden might have predictive value for identifying high-risk patients who have a worse prognosis in melanoma. No significant financial relationships to disclose.


  • Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study

    by Claude Soubrane, Olivier Rixe, Jean-Baptiste Meric, David Khayat, Roger Mouawad

    Biological response parameters during biochemotherapy, including chemotherapy with immune modulating agents, have been studied extensively. Of these parameters, interleukin-6 (IL-6) has been implicated in advanced stage disease and tumour recurrence. However, there is limited information available about the significance of IL-6 in metastatic malignant melanoma (MMM). In this study, we evaluated the possible relationship between serum IL-6 level and overall survival. This retrospective study included 125 patients with MMM. Pretreatment serum IL-6 levels were determined using a highly sensitive enzyme-linked immunosorbent assay (ELISA) test. Kaplan–Meier survival curves were constructed and compared using the log-rank test. Cox proportional analysis was performed to assess the predictors of overall survival, which was calculated from the beginning of biochemotherapy until death. In order to establish the possible relationship between IL-6 level and overall survival, patients were divided into two groups according to a cut-off of 5 pg/ml, corresponding to the first quartile obtained by descriptive statistics of the pretreatment IL-6 level in all patients. Thirty-five patients were in the low IL-6 group and 76 patients were in the high IL-6 group. Based on this stratification, overall survival was shown to be affected by IL-6 serum level: it was higher (24.6 months) in the low IL-6 group when compared with the high IL-6 group (9.7 months) (P=0.0006). Furthermore, Cox multivariate analysis including standard melanoma prognostic factors showed that IL-6, as a variable, lactate dehydrogenase (LDH) and tumour burden were significant prognostic factors for overall survival. On the basis of this evidence, the pretreatment serum IL-6 level is a predictive factor of overall survival in MMM.


  • Clinical significance of serum epidermal growth factor receptor, vascular endothelial growth factor and soluble interleukin-6 in advanced melanoma patients

    by R. Mouawad, O. Rixe, G. Auclerc, D. Khayat, C. Soubrane

    7551 Background and aims: Circulating vascular endothelial growth factor (VEGF), soluble EGFR and soluble interleukin-6 (IL-6) are associated with metastatic malignant melanoma disease. However, their relationship remains unclear. The aims of this study is to correlate serum IL-6 to sVEGF-A, or EGFR levels and to investigate the clinical significance of these parameters on the overall survival in metastatic malignant melanoma. Methods and Patients: using a sensitive enzyme-linked immunosorbent assays, VEGF-A, EGFR and IL-6 were measured in sera of 64 patients with a fully documented history of metastatic malignant melanoma patients in comparison with 30 healthy controls. Results: serum levels of VEGF-A, EGFR, and IL-6 were significantly increased in melanoma patients compared with healthy controls (pp= 0.009), but not sVEGF-A (Chi-square=2.44, P= 0.11 ) or circulating EGFR (Chi Square = 0.01, p= 0.976). Furthermore, using a multivariate analysis (Cox test), tumor burden (p = 0.0051), LDH level (p = 0.006) and IL-6 (p = 0.004) were identified as independent prognostic variables for overall survival but not sVEGF or EGFR. Conclusions: despite the correlations observed between circulating IL-6 and sVEGF-A or EGFR levels, our results indicate that, in patients with metastatic malignant melanoma, only serum IL-6 level is a predictive factor of overall survival but not sVEGF and circulating EGFR . No significant financial relationships to disclose.

  • Changes in circulating VEGF-A levels related to clinical response during biochemotherapy in metastatic malignant melanoma

    by C. Soubrane, R. Mouawad, O. Rixe, J.-P. Spano, M. Gatineau, D. Khayat

    7531 Background: high blood levels of vascular endothelial growth factor (VEGF) appear to be associated with a poor prognosis in advanced cancer, probably as a consequence of its angiogenic and immunosuppressive effects. The prognostic significance of serum VEGF levels and its variation during cancer treatment is still unknown. Objectives: The aim of this study is to evaluate the clinical usefulness of active serum vascular endothelial growth factor (sVEGF-A) levels in metastatic malignant melanoma patients and to investigate the possible relationship between sVEGF-A variations and clinical response during biochemotherapy. Patients and Treatment: The study included 73 patients with a fully documented history of metastatic malignant melanoma. Biochemotherapy consisted of Cisplatinum, rIL-2 and Alpha-interferon in two induction cycles. The assessment of clinical response was performed according to WHO criteria. Sixty seven patients were evaluable: 43 % (29/67) were responding (RC&RP) and 57 % were non-responding (13 SD and 25 PD). Methods: active serum VEGF-A concentrations were measured by an enzyme linked immunosorbent assay (ELISA) in the serum of 26 healthy controls and in 75 MMM patients, before and at the end of treatment. Results: pretreatment serum VEGF-A levels in MMM patients were significantly higher than those in controls (p=0.0017). No significant association was noted between sVEGF-A levels and gender, age and LDH level. Serum VEGF-A levels were higher in patients with high tumor burden as compared to patients with low tumor burden. Before treatment, the sVEGF-A level was not significantly different between R and NR patients; at the end of biochemotherapy, an increase of VEGF-A level was correlated to disease progression (r′=0.53,p=0.01) and a decrease of serum VEGF-A levels was correlated to the objective response to treatment (r′=0.43, p=0.02). Conclusion: these results suggest that changes in sVEGF-A levels may represent a useful biomarker to predict the effect of biochemotherapy in terms of clinical response in patients with metastatic malignant melanoma. No significant financial relationships to disclose.


  • Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy

    by R. Mouawad, E-C. Antoine, M. Gil-Delgado, D. Khayat, C. Soubrane

    Interleukin-1β converting enzymes (ICEs/caspases) are involved in programmed cell death (apoptosis). This study sought to quantify the caspase-1 level in metastatic malignant melanoma patients and to try to establish a correlation between the level of caspase-1 and different parameters related to this pathology. In addition, we evaluated the possible relationship between the clinical response to biochemotherapy and the caspase-1 level. The serum caspase-1 level was determined in 81 metastatic malignant melanoma patients and 50 normal volunteers using enzyme-linked immunosorbent assay (ELISA). Patients received cisplatin, recombinant interleukin-2 (Proleukin) and α-interferon (Roferon A) in two induction cycles, and assessment of clinical response was performed according to World Health Organization (WHO) criteria. The median caspase-1 level in melanoma patients was significantly higher (P = 0.0035) than in control samples. Interestingly, a positive correlation between caspase-1 level and the tumour burden was shown (rs = 0.629, P = 0.009). When the clinical response was taken into consideration, the level of caspase-1 was significantly higher in biochemorefractory patients compared with responding ones (P = 0.04). After treatment, the caspase-1 level remained very high in biochemorefractory patients, while in responding ones no change was observed. Furthermore, a positive correlation between the clinical response and the caspase-1 level was established (rs = 0.404, P = 0.024). In conclusion, we observed an elevated caspase-1 level in metastatic malignant melanoma patients. In addition, the correlations obtained between the caspase-1 level and both the tumour burden and the clinical response to the treatment support the concept that disrupted apoptosis pathways might be involved in the progressive disease of advanced melanoma and/or may confer resistance to treatment.


  • A comparative study of Fas and Fas-ligand expression during melanoma progression

    by C. Soubrane, R. Mouawad, E.C. Antoine, O. Verola, M. Gil-Delgado, D. Khayat

    Background Impaired regulation of apoptosis is known to be associated with the development of various cancers. Fas receptor (APO‐1/CD95) binding to its ligand, Fas‐ligand (Fas‐L), has been shown to trigger apoptosis in various cell types. Objectives In this study, we examined CD95 and Fas‐L expression on primary and metastatic melanoma cells from patients to investigate a potential correlation between these measures of apoptosis and different disease stages.  Patients and methods Primary melanoma cells were obtained after surgical resection from 19 patients and metastatic cells from fine‐needle aspiration of lymph nodes or palpable subcutaneous lesions in 25 patients. Normal skin cells were obtained at skin biopsy of 10 healthy donors.  Results Flow cytometric analysis revealed that CD95 and Fas‐L expression was detected in all the kinds of cell studied. In whole cell suspensions, CD95 expression was significantly higher (P < 0·0001) in normal skin cells than in melanoma cells, whatever the stage studied. By contrast, we observed an increase in Fas‐L expression in melanoma cells compared with normal ones. Subsequently, using a double staining method, we studied these measures on HMB45+ cells, a specific marker for melanoma cells, and found that CD95 expression was significantly higher (P = 0·0005) in primary than in metastatic cells while Fas‐L expression was significantly increased (P = 0·0004) in metastatic compared with primary cells. Furthermore, a relationship was found between CD95 or Fas‐L expression and Breslow thickness; as primary melanoma thickness progressively increased, the percentage of HMB45+ CD95+ cells decreased while that of HMB45+ Fas‐L+ cells concurrently increased.  Conclusions These results suggest that downregulation of CD95 and upregulation of Fas‐L in melanoma might be considered as concomitant with disease progression.


    • 1 December 1997
      • p. S16-21

    Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.

    by E C Antoine, A Benhammouda, A Bernard, A Youssef, N Mortier, M Gozy, D Nizri, G Auclerc, M A Rocher, C L Soubrane, et al.

    This article investigates the safety and efficacy of a simple cisplatin-based biochemotherapy regimen, containing single-agent cisplatin plus recombinant interleukin-2 (rIL-2) and recombinant interferon-alpha (rIFN-alpha), in the treatment of metastatic melanoma. Between December 1990 and April 1997, 129 patients were treated with cisplatin (100 mg/m2, day 0) plus continuous intravenous infusion rIL-2 (18 MIU/m2/day, days 3-6 and days 17-21) and subcutaneous rIFN-alpha (9 MIU three times per week) plus or minus tamoxifen (160 mg/day) on three different protocols. Tumor response, disease-free survival, and overall survival were evaluated for all evaluable patients (N = 127). The overall response rate was 49%, and 10% of patients achieved a complete response. Responses were observed at all sites of metastases. In one case, a patient with a large cutaneous inguinal mass experienced a dramatic regression of that lesion within 1 month. The median disease-free survival was 5 months, and median overall survival was 11 months. Patients who responded had a significant survival advantage over nonresponders, and patients who achieved a complete response had a significant survival advantage over patients with a partial response. Toxicities were manageable and reversible upon discontinuation of therapy. The response rates achieved with this simple biochemotherapy regimen are comparable to those for other cisplatin-based biochemotherapy regimens, which use more complex multiagent chemotherapy regimens. We found no added clinical benefit from the addition of tamoxifen to cisplatin.


    • 1 February 1997
      • Vol. 24, S2-38

    Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.

    by D Coeffic, A Benhammouda, E C Antoine, O Rixe, D Paraiso, G Auclerc, N Renody, E Mularoni, C Soubrane, M Weil, et al.

    The clinical activity and toxicity of the triple combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), cyclophosphamide, and cisplatin was assessed in both previously treated and untreated women with advanced ovarian carcinoma. Paclitaxel 175 mg/m2 was administered over 3 hours following standard premedication (prednisolone, dexchlorpheniramine, and cimetidine). Cisplatin 80 mg/m2 and cyclophosphamide 600 mg/m2 were given 6 to 12 hours after paclitaxel. Treatment was given at 3-week intervals for six cycles. Twenty-seven patients entered the study; 23 were evaluable for toxicity and 17 for response. Paclitaxel appeared to add additional efficacy to the standard cisplatin/cyclophosphamide regimen. Both the overall and complete remission rates were very high (88% and 70%, respectively), and histologically confirmed complete remissions exceeded 60%. Longer follow-up is needed to determine the duration of these responses. The primary toxicities included leukoneutropenia, peripheral neuropathy, asthenia, and alopecia. Only two of 23 patients withdrew because of toxicity, however, and only two treatment cycles were complicated by neutropenic fever requiring intravenous antibiotics. No life-threatening toxicities were encountered, although the peripheral neuropathy was poorly and slowly reversible and may have a significant impact on the patients' quality of life.


    • 1 December 1996
      • Vol. 23, 5-8

    Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.

    by D Coeffic, A Benhammouda, E C Antoine, O Rixe, D Paraiso, G Auclerc, D Nizri, N Renody, J P Grapin, E Mularoni, et al.

    In this phase I/II study, we assessed the impact of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of advanced ovarian carcinoma combined with the standard regimen cisplatin/cyclophosphamide given as follows: paclitaxel 175 mg/m2 (over 3 hours perfusion with standard premedication), cisplatin 80 mg/m2 (6 to 12 hours after paclitaxel), and cyclophosphamide 400 mg/m2. From February 1994 to January 1996, 27 patients (median age, 55 years; age range, 35 to 74 years) were entered into the study. Eight patients had distant metastases and 19 had early locoregional disease (stage III, 18 patients; stage IC, one patient). Twenty-two patients had undergone prior surgery (simple biopsy, six patients; optimally debulked, nine patients; suboptimally debulked, seven patients). Twenty-one patients had received no prior chemotherapy and six were previously treated with at least one platinum-based regimen. A maximum of six courses of paclitaxel/cisplatin/cyclophosphamide were given every 21 days. Twenty-three patients were evaluable for toxicity: neutropenia (World Health Organization grade 3/4), 91% of patients; thrombopenia (World Health Organization grade 3/4), 13% of patients; two episodes of neutropenia with fever; and neurotoxicity grade 3, 17% of patients. Alopecia grade 3 was reported in all patients. No hypersensitivity reactions and no cardiac toxicity was observed. Among 17 patients evaluable for response (patients with stage IV disease or stage III suboptimally debulked), 12 (70%) clinical complete responses (CRs) and three (18%) partial responses were observed. Among the 12 patients with CRs, 10 underwent second-look laparotomy and seven of them (70%) achieved a pathologic CR. In the group of 11 chemotherapy-naive patients evaluable for response, eight (72%) achieved a CR and three (28%) achieved a partial response. This combination seems to be safe, with very acceptable toxicity, and also seems to be highly active in the treatment of patients with advanced ovarian carcinoma.